Patent no. 6 630 507
WebJul 26, 2024 · October 7, 2003: The US government patents CBD as a neuroprotective agent under US Patent No. 6.630.507 It was probably one of the most confusing gestures in federal cannabis law history. The US Department of Health and Human Services received a patent on CBD and other active cannabinoids for their use as neuroprotective therapies. WebUS Patent No.: 5,565,473 Distributed by: MERCK & CO., INC.,Whitehouse Station, NJ 08889, USA Issued July 2008 9628414 SUPPLEMENTAL PATIENT MATERIAL PATIENT INFORMATION SINGULAIR®(SING-u-lair) Tablets, Chewable Tablets, and Oral Granules Generic name: montelukast (mon-te-LOO-kast) sodium Read this information before you …
Patent no. 6 630 507
Did you know?
Web( 12 ) United States Patent Anastassov et al . ( 10 ) Patent No . : US 9 , 814 , 695 B2 ( 45 ) Date of Patent : Nov . 14 , 2024 ( 54 ) OPHTHALMIC SOLUTIONS FOR GLAUCOMA … WebDec 3, 2004 · Date of Patent: July 21, 2024 Assignee: BEIERSDORF AG Inventors: Michael Lessmann, Jens Treu, Kesen Zeng, Yvonne Neumann, Hiroyuki Nakasuka, Ralf Hagens, Philip Drescher Cosmetic preparations containing creatine and/or creatinine and organic thickeners Patent number: 10682534
WebUS 6,630,507 Bl 1 CANNABINOIDS AS ANTIOXIDANTS AND NEUROPROTECTANTS 2 i'l 6THC (known as HU-210) is a superpotent cannabinoid receptor agonist with … WebJan 11, 2024 · The Bilge U.S. Patent No. 6,630,507, The WoodenBoat Forum is sponsored by WoodenBoat Publications, publisher of WoodenBoatmagazine. The Forum is a free …
WebMay 30, 2024 · In a summary of its findings, the United States Department of Health and Human Services found Patent No. 6630507 to “provide a new class of antioxidant drugs that have particular application as neuroprotectants.” The researchers, or “inventors”, even mentioned CBD in their patent claims, citing: WebPat . No . 6 , 630 , 507 issued on Oct . 7 , 2003 and assigned on the patent face to The United States of America , is directed to methods of treating diseases caused by oxidative stress by administering therapeutically effective amounts of a canna bidiol ( CBD ) cannabinoid from cannabis that has substan
WebAccording to patent and trademark attorney, Gregory F. Wesner, the government is being decidedly two-faced on the 6,630,507 topic. On the one hand, the DEA has lumped all cannabis products into the Schedule I category, but on the other hand, synthetic cannabinoid drugs are being approved.
WebThis property is classified as Residential (Single Family). The lot is 208089 square feet, the land value of which is assessed at $405,450.00. There is one building on the property. It … dijddjWebMar 22, 2024 · The United States Patent and Trademark Office (USPTO) Public Search Facility located in Alexandria, VA provides the public access to patent and trademark … beau gunstWebPat . No . 6 , 630 , 507 issued on Oct . 7 , 2003 and assigned on the patent face to The United States of America , is directed to methods of treating diseases caused by oxidative stress by administering therapeutically effective amounts of a canna bidiol ( CBD ) cannabinoid from cannabis that has substan dijck mxWebAug 23, 2024 · A facility operates with respect to a configuration of one or more unmanned aerial vehicles operating as relays between on or more wireless network participant devices and one or more wireless base... dijcksWeb6 , 630 , 507 BI 10 / 2003 Hampson et al . 6 , 730 , 330 B2 5 / 2004 Whittle et al . 7 , 026 , 360 B1 4 / 2006 Festo ... 2024 in Chinese Patent Application No . 201480064243 . X ( with English translation ) . Bhattacharya , et al . , Asia Pacific Journal of Pharmacology , pp . dijc hThe invention also includes identifying and administering antioxidant and neuroprotective compounds (such as cannabidiol) which selectively inhibit the enzyme activity of both 5- and 15-lipoxygenase more than the enzyme activity of 12-lipoxygenase. In addition, such compounds posses low … See more The present invention concerns pharmaceutical compounds and compositions that are useful as tissue protectants, such as neuroprotectants and cardioprotectants. The compounds and compositions may be … See more Given the importance of the NMDA, AMPA and kainate receptors in the mechanism of injury, research efforts have focused on using antagonists to these receptors to interfere with the receptor mediated calcium influx that … See more Permanent injury to the central nervous system (CNS) occurs in a variety of medical conditions, and has been the subject of intense scientific scrutiny in recent years. It is … See more The brain has many redundant blood supplies, which means that its tissue is seldom completely deprived of oxygen, even during acute … See more dijckWebThe European Publication Server is the legally authoritative source of patent applications and patent specifications published by the EPO. With the European Publication Server you can: see all publications of European patent applications (A documents) and specifications of granted European patents (B documents) from 1978 to the present beau haberchak